Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy

You may be eligible if

• 1. Patients must have ever received Pell's lentiviral-based gene-edited immune cell as monotherapy or as combination therapy in clinical trials.
• 2. The last lentiviral-based gene-edited immune cell infusion within 15 years.
• 3. Patient/patient's parent/legal guardian is capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.